Personal Cfo Solutions, LLC Verastem, Inc. Transaction History

Personal Cfo Solutions, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.33 - $10.44 $10,560 - $334,080	-32,000 Reduced 76.19%	10,000 $4,000
Q3 2022 Nov 01, 2022	SELL	$0.92 - $11.16 $4,600 - $55,800	-5,000 Reduced 10.64%	42,000 $36,000
Q2 2022 Aug 05, 2022	SELL	$1.02 - $1.83 $6,492 - $11,647	-6,365 Reduced 11.93%	47,000 $55,000
Q1 2022 May 02, 2022	SELL	$1.06 - $2.1 $14,840 - $29,400	-14,000 Reduced 20.78%	53,365 $75,000
Q4 2021 Feb 11, 2022	SELL	$2.05 - $3.2 $14,349 - $22,400	-7,000 Reduced 9.41%	67,365 $138,000
Q3 2021 Nov 18, 2021	BUY	$2.54 - $4.07 $13,345 - $21,383	5,254 Added 7.6%	74,365 $229,000
Q2 2021 Jul 22, 2021	SELL	$2.57 - $4.85 $48,907 - $92,295	-19,030 Reduced 21.59%	69,111 $281,000
Q1 2021 Apr 21, 2021	BUY	$1.9 - $2.82 $91,467 - $135,757	48,141 Added 120.35%	88,141 $218,000
Q4 2020 Feb 09, 2021	BUY	$1.15 - $2.4 $11,500 - $24,000	10,000 Added 33.33%	40,000 $85,000
Q4 2019 Feb 13, 2020	BUY	$0.86 - $1.44 $17,200 - $28,800	20,000 Added 200.0%	30,000 $40,000
Q3 2019 Nov 13, 2019	BUY	$1.21 - $1.59 $12,100 - $15,900	10,000 New	10,000 $12,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Personal Cfo Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Personal Cfo Solutions, LLC with notifications on news.